CAR-37 T Cells in Hematologic Malignancies
A Phase I Clinical Trial with CAR-37 T Cells for the Treatment of Patients with Relapsed or Refractory CD37+ Hematologic Malignancies
Sponsor: Marcela V. Maus, M.D.,Ph.D.
A PHASE1 clinical study on Hematologic Malignancy and Leukemia, this trial is completed. The trial is conducted by Marcela V. Maus, M.D.,Ph.D. and has accumulated 12 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Jan 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jan 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
Dec 2021 — Jan 2023 [monthly]
Recruiting PHASE1
-
Feb 2021 — Dec 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2019 — Mar 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Marcela V. Maus, M.D.,Ph.D.
For direct contact, visit the study record on ClinicalTrials.gov .